Related Articles
Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences
Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience
XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI
Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma
First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status